Baxter International Inc
$ 18.33
3.04%
19 May - close price
- Market Cap 9,187,983,000 USD
- Current Price $ 18.33
- High / Low $ 18.35 / 17.56
- Stock P/E N/A
- Book Value 11.70
- EPS -1.91
- Next Earning Report -
- Dividend Per Share $0.36
- Dividend Yield 2.08 %
- Next Dividend Date 2026-07-01
- ROA 0.03 %
- ROE -0.15 %
- 52 Week High 31.78
- 52 Week Low 15.73
About
Baxter International Inc. is an American multinational health care company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions.
Analyst Target Price
$22.12
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-12 | 2025-10-30 | 2025-07-31 | 2025-05-01 | 2025-02-20 | 2024-11-08 | 2024-08-06 | 2024-05-02 | 2024-02-08 | 2023-11-02 | 2023-07-27 |
| Reported EPS | 0.36 | 0.44 | 0.69 | 0.59 | 0.55 | 0.58 | 0.49 | 0.68 | 0.65 | 0.88 | 0.68 | 0.55 |
| Estimated EPS | 0.3105 | 0.547 | 0.6 | 0.61 | 0.4832 | 0.52 | 0.78 | 0.66 | 0.61 | 0.86 | 0.67 | 0.61 |
| Surprise | 0.0495 | -0.107 | 0.09 | -0.02 | 0.0668 | 0.06 | -0.29 | 0.02 | 0.04 | 0.02 | 0.01 | -0.06 |
| Surprise Percentage | 15.942% | -19.5612% | 15% | -3.2787% | 13.8245% | 11.5385% | -37.1795% | 3.0303% | 6.5574% | 2.3256% | 1.4925% | -9.8361% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-07-01 | 2026-04-01 | 2026-01-02 | 2025-10-01 | 2025-07-01 | 2025-04-01 | 2025-01-02 | 2024-10-01 | 2024-07-01 | 2024-04-01 |
| Amount | $0.01 | $0.01 | $0.01 | $0.17 | $0.17 | $0.17 | $0.17 | $0.29 | $0.29 | $0.29 |
Next Dividend Records
| Dividend per share (year): | $0.36 |
| Dividend Yield | 2.08% |
| Next Dividend Date | 2026-07-01 |
| Ex-Dividend Date | 2026-05-29 |
Recent News: BAX
2026-05-20 05:37:09
Baxter International Inc. has implemented shareholder-approved changes to its charter and bylaws, resetting the parameters for its board size to a range of seven to twelve directors. This adjustment provides greater flexibility for board composition, aligning with the company's ongoing portfolio restructuring and separation plans. The article details Baxter's core business model, key revenue drivers, and the financial and industry context surrounding these governance changes for US investors.
2026-05-20 00:37:11
Baxter International Inc. is undergoing a significant transformation following the spin-off of its kidney care business, Vantive. The company reported lower sales in Q1 2026 due to the separation but achieved higher adjusted profits through cost savings and portfolio refocusing. Management is dedicated to streamlining operations, optimizing its portfolio, and maintaining financial flexibility through debt reduction and a stable dividend policy.
2026-05-19 17:16:00
Shares of Baxter International Inc. (BAX) rose 3.04% to $18.33 during a generally down market day where the S&P 500 Index and Dow Jones Industrial Average both fell. This marks the second consecutive day of gains for Baxter's stock. The company's performance stood out against its competitors despite the overall market decline.
2026-05-19 08:37:09
Baxter International recently received shareholder approval to amend its certificate of incorporation and bylaws, allowing greater flexibility in board size, now ranging from seven to twelve directors. This governance change comes after a prolonged period of weak share performance for BAX and is seen as an effort to align board oversight with new strategic priorities and shareholder feedback. Investors will be watching for new director appointments and policy changes to gauge the impact of this reset on the company's future performance and financial health.
2026-05-19 07:37:12
Baxter International (NYSE:BAX) recently received shareholder approval to amend its certificate of incorporation and bylaws, adjusting the framework for its board size to between seven and twelve directors. This governance change is viewed as a tool to reshape oversight and potentially bring in fresh expertise, especially in light of the company's weak share performance over the past five years. Investors are now watching for future announcements regarding new director appointments, committee reshuffles, or changes in capital allocation policies to assess how this flexibility will be utilized to address operational and financial challenges.
2026-05-19 02:24:07
Baxter International is gaining attention due to a recent FDA-related development impacting its hospital and kidney-care segments. The company's business model, heavily reliant on essential medical therapies, makes its stock a key indicator for investors monitoring demand for medical devices, regulatory risks, and reimbursement trends in the U.S. healthcare market. Its performance is often evaluated based on execution, quality systems, and margin recovery, making it a monitoring stock rather than a high-growth momentum play.
